Roche to Acquire PathAI in Merger Agreement
Roche has entered a definitive merger agreement to acquire PathAI, a company specializing in digital pathology and AI technology aimed at improving diagnostic workflows. This acquisition, building on previous collaboration, will enhance Roche’s position in digital pathology and precision medicine, with an expected completion in the second half of the year. Roche will pay $750 million upfront with potential additional payments of up to $300 million.
Basel, 7 May 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to the closing of the transaction, which is expected in the second half of the year, the acquired entity will become part of the Diagnostics division.